Data analysis from a large-scale retrospective study assessing the clinical advantages of the FIZE kUO system in intensive care settings; key insights to be presented at 2025WCAC, October 10–11, in Singapore, by Prof. Moti Klein
NEW YORK, July 9, 2025 /PRNewswire/ — FIZE Medical, a leader in smart fluid management solutions for critically ill patients, announced today that interim findings from a large-scale retrospective observational study evaluating its flagship technology, the FIZE kUO digital urine output monitoring system, will be presented at the upcoming 2025 World Critical Care and Anesthesiology Conference (2025WCAC) conference in Singapore.
Prof. Motti Klein is Director of the Intensive Care Unit at Soroka Medical Center, one of Israel’s leading academic hospitals. He leads clinical research focused on critical care innovation, including a study evaluating real-time urine output monitoring for earlier AKI recognition.
Dror Lemel is the CEO of FIZE Medical, a MedTech company developing real-time urine output monitoring and decision-support tools to advance kidney care in the ICU. FIZE’s technology aims to improve early AKI detection and optimize fluid management.
Led by Prof. Moti Klein, Director of Intensive Care at Soroka Medical Center, the study was designed as a clinical investigation using retrospective EMR data from ICU patients. Preliminary study results suggest that minute-by-minute UO data may transform the Furosemide Stress Test (FST) workflow, drastically reducing the time to decision by 75% and enabling faster assessment of AKI risk.
Clinical decision-making is only as good as the data clinicians have. Timely and high-quality data on kidney function—delivered in real time—can help detect Acute Kidney Injury (AKI), a common and often preventable ICU complication with significant clinical and economic impact. Yet current manual methods fall short, lacking the precision and continuity required for timely intervention.
“This study is a critical step toward validating whether real-time, digitized data can empower clinicians to detect kidney injury earlier, intervene with greater precision, and ultimately reduce preventable complications” Prof. Moti Klein, Director of Intensive Care at Soroka Medical Center-“The potential clinical impact is significant: improving fluid responsiveness assessments, reducing AKI progression, and elevating the standard of care for critically ill patients.”
AKI affects over 50% of ICU patients and is strongly associated with higher mortality rates, longer hospitalizations, increased dialysis rates, and substantial care costs. Early recognition is essential. For timely intervention and avoidance of damage progression. Urine output is an early and strong predictor of acute kidney injury and associated mortality, which has been underutilized due to the challenge of continuously obtaining accurate measurements.[1]
FIZE Medical’s flagship platform, FIZE kUO, delivers real-time, urine output monitoring with full integration into the electronic medical record (EMR). By providing continuous trend visibility, FIZE equips ICU teams with timely, actionable insights to support earlier AKI detection, optimize fluid therapy, and improve response to hemodynamic instability.
The Clinical Pipeline
“This marks the first milestone in our robust clinical pipeline to establish the value of real-time urine output data in critical care,” said Dror Zerem, the CEO. “We’re proud to collaborate with leading institutions and experts like Prof. Klein, who share our mission to digitize critical care workflows. Alongside the operational advantages of the FIZE kUO platform, this study represents a significant step toward building the clinical evidence base for smarter, data-driven fluid management.”
FIZE Medical continues to expand its research partnerships and clinical evaluations globally, supporting hospitals in their transition to precision fluid management and AKI prevention protocols. Key insights from this study will be presented at the World Critical Care and Anesthesiology Conference (2025WCAC), October 10 – 11, in Singapore.
About FIZE Medical
FIZE Medical provides smart fluid management solutions designed for the critically ill patients in the most complex and dynamic hospital environments. Its flagship product, FIZE kUO, offers continuous, digital urine output data to support early detection of kidney injury and optimization of fluid therapy in ICU and OR. FIZE Medical is committed to redefining fluid management through continuous innovation, digital integration, and clinical evidence.
[1] Malbrain, Manu L N G et al. “Urine output is an early and strong predictor of acute kidney injury and associated mortality: a systematic literature review of 50 clinical studies.” Annals of intensive care vol. 14,1 110. 9 Jul. 2024, doi:10.1186/s13613-024-01342-x
Photo – https://mma.prnewswire.com/media/2727715/FIZE_Medical_1.jpg
Photo – https://mma.prnewswire.com/media/2727714/FIZE_Medical_2.jpg
SOURCE FIZE Medical
